Overview

Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection

Status:
Not yet recruiting
Trial end date:
2022-03-31
Target enrollment:
0
Participant gender:
All
Summary
This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and tetracycline for 14 days (LBMT)
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Incheon St.Mary's Hospital
Treatments:
Dexlansoprazole
Lansoprazole
Criteria
Inclusion Criteria:

patients who male or female aged 19 to 75 years old and fall under the following conditions
with confirmed helicobacter pylori infection

Exclusion Criteria:

1. patients who have H.pylori eradication history

2. patients with history of gastric cancer surgery

3. patients who have taken antibiotics within 4 weeks prior to trial

4. a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug
containing rilpivirine

5. pregnant or breastfeeding women